As we approach some of the biggest Life Sciences events over the next few weeks and months, I wanted to share with you some of the videos and eBooks produced by our training experts, to give you a range of industry insights, and to get a flavour of the training available either to your new recruits, or to senior managers and suppliers to the industry needing a big picture refresher.
I hope you will therefor enjoy this short video, taken from the 12 Hour MBA in Clinical Trials online training course. The 12 Hour MBA in Clinical Trials is an introductory-level online training course designed to bridge knowledge gaps. It is most useful to new entrants, senior managers needing a big picture refresher and professional advisors and suppliers to the field.
In this video, trainer Dr. Brian Gennery explains the process of making the quantum leap to testing a drug on a human being for the first time, and outlines the steps involved in getting to that point. I hope you will enjoy it.
View the full course
The full course comprises 12 online modules. All the modules include online video, downloadable course material and an online quiz.
You'll have access to the course for 90 days. So, you can take the course at your own pace and from the comfort of your own desk.
In less than 12 hours you'll:
- Learn how to create a clinical development plan
- Understand what to expect at phases 1, 2 and 3 of the clinical development process.
- Understand how to design a protocol
Meet the trainer – an expert in Clinical Trials
Dr Brian Gennery has a visiting appointment as Senior Lecturer in Clinical Pharmacology and Translational Medicine at King's College, London.
He has worked in pharmaceutical research and development for 35 years, having worked for Boehringer Ingelheim, Eli Lilly and Chiroscience. He was a co-founder or Arakis and is a past President of the Faculty of Pharmaceutical Medicine.
He has acted as the principle investigator on a clinical trial, consults for four small pharmaceutical companies and has chaired the Independent Science Advisory Committee on databases at the MHRA. He has just retired as a member of the Medicines Committee of the Royal College of Paediatrics and Child Health and has acted as an expert for both the FP6 and FP7 research programmes at the EU Commission.